NAMPT haploinsufficiency is a therapeutic vulnerability to NAMPT inhibition in -7/-7q MDS

Nemo Ikonen,[1,2] Tanja Ruokoranta,[1,3] Salla Hyyppä,[1] Ella Sinervuori,[1,2] Juho J. Miettinen,[1,2] Joseph Saad,[1,2] Markus Vähä-Koskela,[1,2] and Caroline A. Heckman[1,2]

[1]Institute for Molecular Medicine Finland - FIMM, Helsinki Institute of Life Science, University of Helsinki, Finland

[2]iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki and Helsinki University Hospital, Finland

[3]Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

Correspondence: Caroline Heckman, PhD, Institute for Molecular Medicine Finland, University of Helsinki, Tukholmankatu 8 (P.O. Box 20), FI-00290 Helsinki, Finland, Telephone: +358 50 4156769, Email: caroline.heckman@helsinki.fi

Text word count: 719 / 700 **Figures:** 2/2

References: 20 / 12 **Supplement:** Yes

Abstract

Chromosome 7 abnormalities -7 and -7q define a high-risk subset of myelodysplastic syndromes (MDS) with poor prognosis. The *NAMPT* gene, located at 7q22.3, encodes a rate limiting enzyme (nicotinamide phosphoribosyl transferase) in the NAD+ salvage pathway. Several inhibitors of NAMPT have been developed but their activity in MDS has

not been previously described. In this study we investigated if MDS myeloblasts are susceptible to NAMPT inhibition. We show that primary bone marrow cells from patients with -7/-7q MDS exhibit strong and select sensitivity. Bulk viability assays and single cell, multiparametric flow cytometry confirmed enhanced NAMPT inhibitor sensitivity across leukemic cell populations, especially CD34+CD38+ blasts from -7/-7q MDS samples compared to non -7/-7q MDS and healthy donor bone marrow cells. The NAMPT inhibitor KPT-9274 combined with BCL2 inhibitor venetoclax was particularly effective at targeting MDS blasts compared to NAMPT inhibition alone. MDS samples with -7/-7q also showed significantly lower *NAMPT* expression compared to the non -7/-7q samples, indicative of haploinsufficient gene expression profile. In conclusion, these findings support *NAMPT* haploinsufficiency as a vulnerability and as biomarker for NAMPT inhibitor activity in -7/-7q MDS.

38 **Research letter**

39 Monosomy 7 and deletion of the q arm of chromosome 7 (-7/-7q) are recurrent alterations
40 in myelodysplastic syndromes (MDS) present in approximately 10% of patients, and are
41 associated with poor prognosis, shorter survival, and increased risk of progression to
42 acute myeloid leukemia (AML) (1,2). Nicotinamide phosphoribosyl transferase (NAMPT),
43 encoded by the *NAMPT* gene at chromosome 7q22.3, is the rate limiting enzyme in the
44 nicotinamide adenine dinucleotide (NAD+) salvage pathway (3). NAMPT inhibitors have
45 shown good efficacy in preclinical studies of hematological malignancies as they
46 effectively target cancer cell metabolism by blocking the salvage pathway which leads to
47 NAD+ depletion and cell death (4–7). Previous studies have shown that AML blasts with
48 -7/-7q are exceptionally sensitive to NAMPT inhibitors, with the sensitivity caused by
49 *NAMPT* gene haploinsufficiency as a result of -7/-7q (8,9). The objective of this study was
50 to investigate whether MDS blasts with -7/-7q are similarly susceptible to NAMPT
51 inhibition, and if *NAMPT* haploinsufficiency could be a biomarker for NAMPT inhibitor
52 activity in MDS.

53 The patient sample cohort is described in **Supplemental Table 1,** and the methods are
54 described in full in the **Supplemental Material** and illustrated in **Figure 1A.** We first
55 assessed the bulk cell viability-based drug sensitivity screening results from bone marrow
56 (BM) cell samples collected from patients with MDS and compared it to data from BM
57 mononuclear cells (MNCs) from healthy donors that were published previously (8,10).
58 MDS and healthy donor BM-MNCs were incubated with the NAMPT inhibitor daporinad
59 for 72 hours, and cell viability was measured using the CellTiter-Glo (CTG) and CellTox
60 Green (CTxG) assays. Dose response curves (**Figure 1B–C**) were summarized as drug

61 sensitivity scores (DSS) **(Figure 1D–E**, **Supplemental Tables 2–3**). Overall, MDS
62 samples were significantly more sensitive to NAMPT inhibition compared to the healthy
63 donor samples in the CTG assay (**Supplemental Figure 1A**), indicative of an actionable
64 therapeutic window and in line with previous studies in AML (4,5,8,11). The sample
65 carrying -7/-7q was found to be the most responsive sample to NAMPT inhibition (**Figure**
66 **1D**). A similar trend was observed in the CTxG assay, with the -7/-7q MDS sample being
67 the most sensitive, but there was no significant difference between MDS and healthy
68 donor samples (**Figure 1E, Supplemental Figure 1B)**. To assess if the -7/-7q MDS
69 samples express less *NAMPT* due to *NAMPT* gene haploinsufficiency, we analyzed the
70 gene expression in CD34+CD38- cells which showed that samples with -7/-7q had
71 significantly lower *NAMPT* expression, indicating a haploinsufficient gene expression
72 profile (**Figure 1F**, **Supplemental Table 4**).

73 To investigate NAMPT inhibitor activity in different cell subpopulations, we performed flow
74 cytometry-based drug sensitivity analysis. MDS BM-MNCs were incubated with the
75 NAMPT inhibitors daporinad and KPT-9274 for 72 hours (**Supplemental Table 5**) and
76 subsequently stained with an antibody panel (**Supplemental Table 6**). We observed that
77 NAMPT inhibitors effectively target the different myeloblast populations in MDS samples
78 and that CD34+, CD117+, CD34+CD117+, CD34+CD38- and CD34+CD38+ blasts from
79 -7/-7q MDS were significantly more sensitive to NAMPT inhibition by daporinad compared
80 to non -7/-7q MDS blasts (**Figure 2A, Supplemental Figure 2**, **Supplemental Table 7**).
81 Similar trends were observed for KPT-9274, however, the results were not significant
82 (**Figure 2B**). Additionally, CD34+CD38+ blasts were more sensitive to daporinad and
83 KPT-9274 than CD3+ T lymphocyte cells representing a healthy cell population control

84 and CD14+ monocytic cell population in -7/-7q samples (**Supplemental Figure 3A-B**).
85 These results indicate that the cell populations with a leukemic phenotype, particularly
86 CD34+CD38+, are sensitive to NAMPT inhibition.

87 Next, we assessed KPT-9274 efficacy with three different clinically relevant drug
88 combinations: venetoclax, azacitidine and cytarabine. We observed that the combination
89 of KPT-9274 and venetoclax was significantly more cytotoxic towards CD34+CD38- cells
90 in samples with -7/-7q compared to KPT-9274 alone (**Figure 2C**), and the combination
91 was significantly more cytotoxic in -7/-7q compared to non -7/-7q samples (**Figure 2C**).
92 The addition of azacitidine or cytarabine did not significantly decrease the cell viability
93 (**Supplemental Table 8**, **Supplemental Figure 3C–D**).

94 The data from this study demonstrate that NAMPT inhibitors are highly active in -7/-7q
95 MDS *ex vivo* and establish *NAMPT* haploinsufficiency as a vulnerability and biomarker
96 for NAMPT inhibitor activity. The findings suggest that patients with MDS, especially those
97 with -7/-7q, could benefit from NAMPT inhibitors, and support expanded investigations,
98 including clinical evaluation, of NAMPT inhibitors in high-risk MDS.

99

100 **Declarations**

101 **Ethics approval and consent to participate**

102 Bone marrow (BM) or peripheral blood (PB) samples were collected from patients with
103 MDS after informed consent using protocols approved by the Institutional Review Board
104 at the Helsinki University Hospital (permit numbers 239/13/03/00/2010 and

303/13/03/01/2011, Helsinki University Hospital Ethics Committee) in compliance with the Declaration of Helsinki.

Consent for publication

Not applicable

Availability of data and materials: The data generated or analyzed during this study are included in this manuscript and its supplementary files. RNA counts data have been deposited to Zenodo: link and DOI will be provided following manuscript acceptance. All other relevant data to the current study are available from the corresponding author (Caroline Heckman, caroline.heckman@helsinki.fi) on reasonable request.

Competing interest: C.A.H. has received research funding for unrelated work from Oncopeptides, IMI2 projects HARMONY and HARMONY PLUS, WNTResearch, Orion, Kronos Bio, Novartis, Celgene, and Zentalis Pharmaceuticals; has been awarded honoraria from Amgen and consultancy fees from Autolus. M.V.-K has received research funding from Immunocore UK for unrelated work. Other authors declare no conflicts of interest.

Funding: This work was supported by the University of Helsinki, Cancer Foundation Finland, the Academy of Finland (grants 334781, 1357686, 1320185) (C.A.H.), the Sigrid Jusélius Foundation, Veritautien tutkimussäätiö (N.I.), Ida Montin Foundation (N.I.), the Finnish Cultural Foundation (N.I.), Orion Research Foundation (N.I.), Finnish Hematology Association (N.I.) and Instrumentarium Science Foundation (N.I.).

Authors' contributions: N.I., T.R., S.H., E.S., J.M. and J.S. planned and conducted experiments. N.I. analyzed and interpreted the data. N.I., and C.A.H wrote the

manuscript. M.V.-K. and C.A.H. provided leadership and funding. All authors read and approved the manuscript.

Acknowledgements: The authors thank the patients and clinics who made this study possible. The authors also thank the Finnish Hematology Registry and Clinical Biobank (FHRB) for providing the samples and clinical information. Instruments, drug plate preparation and part of the flow cytometry analysis were carried out by the FIMM High Throughput Biomedicine Unit, and library preparation and RNA sequencing were performed by Biomedicum Functional Genomics Unit and FIMM Genomics NGS Sequencing unit, which all are hosted by the University of Helsinki and supported by HiLIFE and Biocenter Finland. Cell sorting and analysis were performed at the HiLife Flow Cytometry Unit, University of Helsinki. N.I. is a Ph.D. candidate at the University of Helsinki. This work is submitted in partial fulfillment of the requirement for the Ph.D. The authors would like to express gratitude to Minna Suvela and Alun Parsons for their role in processing the samples for the study and to Natalia Mokrzecka for her help with the flow cytometry.

References

1. Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007 Dec 15;110(13):4385–95. doi:10.1182/blood-2007-03-082404

2. Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, et al. New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. J Clin Oncol. 2012 Mar 10;30(8):820–9. doi:10.1200/JCO.2011.35.6394 PubMed PMID: 22331955; PubMed Central PMCID: PMC4874200.

3. Revollo JR, Grimm AA, Imai S ichiro. The NAD Biosynthesis Pathway Mediated by Nicotinamide Phosphoribosyltransferase Regulates Sir2 Activity in Mammalian Cells*. J Biol Chem. 2004 Dec 3;279(49):50754–63. doi:10.1074/jbc.M408388200

4. Nahimana A, Attinger A, Aubry D, Greaney P, Ireson C, Thougaard AV, et al. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood. 2009 Apr 2;113(14):3276–86. doi:10.1182/blood-2008-08-173369 PubMed PMID: 19196867.

5. Mitchell SR, Larkin K, Grieselhuber NR, Lai TH, Cannon M, Orwick S, et al. Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia. Blood Adv. 2019 Feb 12;3(3):242–55. doi:10.1182/bloodadvances.2018024182 PubMed PMID: 30692102; PubMed Central PMCID: PMC6373756.

6. Korotchkina L, Kazyulkin D, Komarov PG, Polinsky A, Andrianova EL, Joshi S, et al. OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis. Leukemia. 2020 Jul;34(7):1828–39. doi:10.1038/s41375-019-0692-5

7. Åleskog A, Bashir-Hassan S, Hovstadius P, Kristensen J, Höglund M, Tholander B, et al. Activity of CHS 828 in primary cultures of human hematological and solid tumors in vitro. Anticancer Drugs. 2001 Nov;12(10):821.

8. Eldfors S, Saad J, Ikonen N, Malani D, Vähä-Koskela M, Gjertsen BT, et al. Monosomy 7/del(7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia. Blood Adv. 2024 Mar 27;8(7):1621–33. doi:10.1182/bloodadvances.2023010435

9. Senagolage MD, Blaylock HZ, Khan S, Skuli SJ, Carroll MP, McNerney ME. NAMPT haploinsufficiency is a collateral lethal therapeutic vulnerability in high-risk myeloid malignancies with TP53 inactivation. Blood Neoplasia. 2025 Aug 20;2(3):100119. doi:10.1016/j.bneo.2025.100119

10. Malani D, Kumar A, Brück O, Kontro M, Yadav B, Hellesøy M, et al. Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. Cancer Discov. 2022 Feb;12(2):388–401. doi:10.1158/2159-8290.CD-21-0410 PubMed PMID: 34789538; PubMed Central PMCID: PMC9762335.

11. Jones CL, Stevens BM, Pollyea DA, Culp-Hill R, Reisz JA, Nemkov T, et al. Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells. Cell Stem Cell. 2020 Nov 5;27(5):748-764.e4. doi:10.1016/j.stem.2020.07.021 PubMed PMID: 32822582; PubMed Central PMCID: PMC7655603.

191 **Figure legends**

192 **Figure 1. MDS samples are sensitive to NAMPT inhibition.** A) Illustration of the
193 experimental workflow. Created with Biorender.com. B) Dose response curves for
194 CellTiter-Glo-based and C) CellTox-Green-based bulk cell viability assays. Samples were
195 treated with daporinad in 5 concentrations for 72 hours. D) Daporinad drug sensitivity
196 score (DSS) values for MDS (n=6) and healthy (n=14) samples for CellTiter-Glo assay.
197 Higher DSS indicates greater sensitivity. Data for healthy samples were summarized as
198 one curve with standard deviations. E) Daporinad DSS values for MDS (n=7) and healthy
199 (n=5) samples for CellTox Green assay. Data for healthy samples (n=5) were summarized
200 as one score with standard deviation. F) *NAMPT* gene expression z-scores were
201 compared between -7/-7q (n=5) and non -7/-7q MDS samples (n=25) using a the two-
202 sample t-test. Gene expression profiles were analyzed from sorted CD34+CD38- cells.

203 **Figure 2. Flow cytometry-based drug sensitivity screening shows that MDS**
204 **samples with -7/-7q are highly sensitive to NAMPT inhibition.** Drug sensitivity scores
205 for the different cell populations for A) daporinad and B) KPT-9274. MDS samples with
206 (n=8) and without (n=12) -7/-7q were incubated with the inhibitors for 72 hours and dose
207 response curves were summarized as DSS values. Higher DSS indicates greater
208 sensitivity. Samples with -7/-7q were compared to those without -7/-7q using a two-
209 sample t-test. C) Comparison of cell viability between single agents and the combination
210 of 1000 nM of KPT-9274 and 10 nM of venetoclax in CD34+CD38- cells in -7/-7q (n=5)
211 and non -7/-7q (n=5) MDS samples. Samples were treated with the inhibitors for 72 hours,
212 after which the cells were stained with detection antibodies to separate different cell types.

213 Comparisons were done using a two-sample t-test and *P* values were adjusted using the

214 Benjamini-Hochberg method.

215

Figure 1.


A)
MDS patient samples n=41
Mononuclear cells
72-hour incubation with the drug panel
Bulk viability readout (CTG and CTxG) n=7
Flow cytometry based viability readout n=20
CTG and Flow assay
Cell viability (%)
DSS low resistant
DSS high sensitive
Concentration [M]
CTxG assay
Cell death (%)
DSS high sensitive
DSS low resistant
Concentration [M]
Cell sorting for CD34+CD38- cells
RNA sequencing n=30
B)
CellTiter-Glo
Cell viability (%)
Daporinad [nM]
-7/-7q
Non -7/-7q
Healthy
C)
CellTox Green
Cell death (%)
Daporinad [nM]
-7/-7q
Non -7/-7q
Healthy
D)
CellTiter-Glo
DSS
MDS.31
MDS.13
MDS.37
MDS.6
MDS.36
MDS.1
Healthy
-7/-7q
Non -7/-7q
Healthy
E)
CellTox Green
DSS
MDS.31
MDS.13
Healthy
MDS.1
MDS.37
MDS.6
MDS.36
MDS.27
-7/-7q
Non -7/-7q
Healthy
F)
P = .018
NAMPT expression z-score
-7/-7q n=5
Non -7/-7q n=25

Figure 2.


A)
Flow cytometry assay
Daporinad DSS
-7/-7q
Non -7/-7q
***
**
***
*
*
CD34+
CD117+
CD38+
CD34+CD117+
CD34+CD38-
CD34+CD38+
CD14+
CD3+
B)
Flow cytometry assay
KPT-9274 DSS
-7/-7q
Non -7/-7q
CD34+
CD117+
CD38+
CD34+CD117+
CD34+CD38-
CD34+CD38+
CD14+
CD3+
C)
CD34+CD38- cells
Cell viability (%)
P = .034
P = .025
-7/-7q
Non -7/-7q
KPT-9274 1000nM
Venetoclax 10nM
KPT-9274 1000nM Venetoclax 10nM